AA
AARD.NS
—
NSE (India)
Paper Products
Aard.Ns
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
13,6 %
ROE
34,9 %
Net margin
9,0 %
Debt / equity
1,35
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$6,33
Open
$6,70
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
AARD.NS operates in the paper products industry, producing and selling paper-based goods, primarily generating revenue through the sale of these products to commercial and industrial customers.
Business. Aardvark Therapeutics Inc (AARD.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification92 %
SectorBasic Materials
Business sectorApplied Resources
IndustryPaper Products
Generated · model-assisted
Sell-side consensus
BUY12 analysts
6 buy4 hold2 sell
Avg 12m price target14,80
Analyst recommendations
12 analysts · consensus BuyBuy6
Hold4
Sell2
12-month price target
14,80
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
12 analysts · indicative
Ownership→
AQR Capital Management, LLC
largest disclosed fund holder
Profitability→
34,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to AARD.NS. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Aardvark Therapeutics Inc (AARD.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification92 %
SectorBasic Materials
Business sectorApplied Resources
IndustryPaper Products
AI synthesis
GENERATEDAARD.NS has a debt-to-equity ratio of 1.35, indicating a moderate reliance on debt financing, and a current ratio of 1.38, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's liquidity position is assessed as medium, with a key flag indicating that net cash is negative after subtracting total debt.
The company's profitability is reflected in a return on equity (ROE) of 34.87% and a return on assets (ROA) of 12.37%, both of which are strong indicators of efficient use of equity and assets to generate profit. These metrics suggest that AARD.NS is performing well in terms of profitability relative to its capital base.
AARD.NS does not disclose specific segment or geographic revenue breakdowns in the provided data, so it is not possible to assess revenue concentration or geographic exposure at this time. However, the company's primary business activity is in the paper products industry, which is typically less geographically diversified.
The company's growth trajectory is not explicitly detailed in the provided data, and no specific numeric deltas for the current or next fiscal year are available. However, the company's operating cash flow of INR 54.79 million and free cash flow of INR 126.68 million suggest a positive cash flow position, which could support future growth initiatives.
The risk assessment for AARD.NS indicates a medium liquidity risk and a low dilution risk. The company's key financial risk is the negative net cash position after accounting for total debt, which could affect its ability to meet short-term obligations. No significant dilution sources are identified in the provided data, and the dilution risk is assessed as low.
No recent events, such as filings or transcripts, are provided in the input data to inform the company's recent developments or strategic direction.
Key takeaways
- AARD.NS has a strong return on equity (34.87%) and return on assets (12.37%), indicating efficient use of capital.
- The company's debt-to-equity ratio of 1.35 suggests a moderate level of leverage.
- AARD.NS has a current ratio of 1.38, indicating it has sufficient short-term assets to cover its short-term liabilities.
- The company's liquidity risk is assessed as medium, with a key flag indicating a negative net cash position after subtracting total debt.
- No significant dilution risk is identified, and the company's dilution risk is assessed as low.
- The company's growth trajectory and geographic exposure are not explicitly detailed in the provided data.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$87,85
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$294.7M
Net cashⓘ
-$396.6M
Current ratioⓘ
1.4
Debt / equityⓘ
1.4
ROAⓘ
12.4%
ROEⓘ
34.9%
Cash conversionⓘ
53.0%
CapEx / revenueⓘ
-0.1%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries2
EX21:293d26853ab0EX21:293d26853ab0Subsidiarie97%
EX21:9851ecf3559cEX21:9851ecf3559cSubsidiarie97%
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 42 %
EPS
Consensus EPS
-3,59
Predicted surprise
+0,07
Beat probability
42 %
Analysts
12
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio -0,05 · as of 2026-07-17 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$3,00
Mean$14,80
Median$8,00
High$45,00
Spot$87,85
−83.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin13,6 %Best in class
Net Margin9,0 %Above P75
ROE34,9 %Best in class
Capex / Rev-0,1 %Above P75
D/E1,35Bottom quartile
Cash Conv0,53Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 364 637 sh3 exercises · 3 grants4 insiders
- Chief Medical Officer · Stock option (right to buy) → Common StockDisposed 70 549 @ $13,48grant · 2026-02-09
- Director, Chief Executive Officer, 10% owner · Stock option (right to buy) → Common StockDisposed 203 851 @ $13,48grant · 2026-02-09
- Chief Financial Officer · Stock option (right to buy) → Common StockDisposed 70 549 @ $13,48grant · 2026-02-09
- Director, Chief Executive Officer, 10% owner · Stock option (right to buy) → Common StockDisposed 1 229 @ $4,24exercise · 2025-10-15
- Chief Operating Officer · Stock option (right to buy) → Common StockDisposed 1 250 @ $4,24exercise · 2025-10-15
- Director, Chief Executive Officer, 10% owner · Stock option (right to buy) → Common StockDisposed 17 209 @ $4,24exercise · 2025-08-28
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- AARD.NS Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net buying8 buys · 0 sellsnet $450K3 insiders · last 365d
- Chief Financial Officer · Common StockBought 3 000 @ $14,40$43K · 2025-12-11
- Director, Chief Executive Officer, 10% owner · Common StockBought 7 000 @ $14,48$101K · 2025-12-11
- Director, Chief Executive Officer, 10% owner · Common StockOther 1 229 @ $4,24$5K · 2025-10-15
- Chief Operating Officer · Common StockOther 1 250 @ $4,24$5K · 2025-10-15
- Director, Chief Executive Officer, 10% owner · Common StockBought 3 500 @ $9,94$35K · 2025-09-15
- Director, Chief Executive Officer, 10% owner · Common StockBought 6 500 @ $9,51$62K · 2025-09-15
- Director, Chief Executive Officer, 10% owner · Common StockBought 5 000 @ $8,50$43K · 2025-09-12
- Director, Chief Executive Officer, 10% owner · Common StockBought 6 000 @ $7,82$47K · 2025-09-11
- Director, Chief Executive Officer, 10% owner · Common StockBought 9 000 @ $7,91$71K · 2025-09-10
- Chief Financial Officer · Common StockBought 6 000 @ $8,07$48K · 2025-09-09
- Director, Chief Executive Officer, 10% owner · Common StockOther 17 209 @ $4,24$73K · 2025-08-28
Short positioning
651.8Kshares short+23.4% vs prior
1days to cover
40.5%short of daily vol
14fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
AARD.NSCanonical
NSE (India) · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 43.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -23.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -54.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 43.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -199.5%Derived (calculated)
- Current ratio (FY 2025-12-31): 10.61xDerived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 181.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -179.7%Derived (calculated)
- Return on assets (FY 2025-12-31): -49.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.10xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 295.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 51.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 95.6%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -12.8%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -175.3%Derived (calculated)
- Total liabilities (annual): USD 10.55MSEC XBRL filing
- Current assets (annual): USD 111.89MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -3SEC XBRL filing
- Total operating expenses (annual): USD 62.73MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -3SEC XBRL filing
- Cash & equivalents (annual): USD 47.05MSEC XBRL filing
- Net income (annual): USD -57.59MSEC XBRL filing
- Operating income (annual): USD -62.73MSEC XBRL filing
- Shareholders' equity (annual): USD 106.63MSEC XBRL filing
Showing 24 of 51 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-12 21:55 UTCEVENTHa Price Move AARD extraordinary up move (49.4% 1d, 4.03x sigma) on x16.66 volume
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-02-09 00:00 UTCINSIDER3 insider transactions — 2026-02 3 derivative
2026-02-09INSIDERSun Nelson disposed of 70.5k sh Stock option (right to buy) — Chief Financial Officer
2026-02-09INSIDERJaiman Manasi disposed of 70.5k sh Stock option (right to buy) — Chief Medical Officer
2026-02-09INSIDERLee Tien-Li disposed of 203.9k sh Stock option (right to buy) — Director, Chief Executive Officer, 10% owner
2025-12-11 00:00 UTCINSIDER2 insider transactions — 2025-12 · net buy $145k
2025-12-11INSIDERSun Nelson bought 3.0k sh — Chief Financial Officer ~$43k
2025-12-11INSIDERLee Tien-Li bought 7.0k sh — Director, Chief Executive Officer, 10% owner ~$101k
2025-10-15 00:00 UTCINSIDER4 insider transactions — 2025-10 2 derivative
2025-10-15INSIDERLee Tien-Li transacted 1.2k sh — Director, Chief Executive Officer, 10% owner ~$5k
2025-10-15INSIDERJones Bryan transacted 1.2k sh — Chief Operating Officer ~$5k
2025-10-15INSIDERJones Bryan disposed of 1.2k sh Stock option (right to buy) — Chief Operating Officer
2025-10-15INSIDERLee Tien-Li disposed of 1.2k sh Stock option (right to buy) — Director, Chief Executive Officer, 10% owner
2025-09-15 00:00 UTCINSIDER6 insider transactions — 2025-09 · net buy $306k
2025-09-15INSIDERLee Tien-Li bought 6.5k sh — Director, Chief Executive Officer, 10% owner ~$62k
2025-09-15INSIDERLee Tien-Li bought 3.5k sh — Director, Chief Executive Officer, 10% owner ~$35k
2025-09-12INSIDERLee Tien-Li bought 5.0k sh — Director, Chief Executive Officer, 10% owner ~$43k
2025-09-11INSIDERLee Tien-Li bought 6.0k sh — Director, Chief Executive Officer, 10% owner ~$47k
2025-09-10INSIDERLee Tien-Li bought 9.0k sh — Director, Chief Executive Officer, 10% owner ~$71k
2025-09-09INSIDERSun Nelson bought 6.0k sh — Chief Financial Officer ~$48k
2025-08-28 00:00 UTCINSIDER2 insider transactions — 2025-08 1 derivative
2025-08-28INSIDERLee Tien-Li transacted 17.2k sh — Director, Chief Executive Officer, 10% owner ~$73k
2025-08-28INSIDERLee Tien-Li disposed of 17.2k sh Stock option (right to buy) — Director, Chief Executive Officer, 10% owner
2025-06-11 00:00 UTCINSIDER8 insider transactions — 2025-06 8 derivative
2025-02-14 00:00 UTCINSIDER20 insider transactions — 2025-02 · net buy $13.4M 8 derivative
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage